Read Moderna Vaccine latest news on The Economic Times. Moderna Vaccine updates, Moderna Vaccine videos & more.

A groundbreaking immunotherapy treatment for rectal cancer, developed through pioneering research at Memorial Sloan Kettering Cancer Center (MSK) with critical early-stage funding from Swim Across ...

FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic ...

The U.S. Food and Drug Administration (FDA) on Thursday granted accelerated approval to AstraZeneca Plc’s AZN Ultomiris ...

AstraZeneca PLC announced that Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) ...

AstraZeneca’s Zegfrovy demonstrated a 46% overall response rate in a trial supporting its accelerated FDA approval, as the ...

ZEGFROVY is now available in the US for post-platinum EGFR exon 20 insertion NSCLC after a 46% response rate in WU-KONG1B.

AstraZeneca has notched another indication to the belt of its rare disease therapy Ultomiris (ravulizumab) through an accelerated US approval in primary immunoglobulin A nephropat ...

The accelerated approval makes Ultomiris, or ravulizumab, the first and only C5 complement inhibitor approved for this use. Novartis' Fabhalta, or iptacopan, is also approved for this indication but ...

The US regulator has granted Ultomiris accelerated approval in a rare kidney disease, but continued approval hinges on a ...

October 2026Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathyBased on I CAN Phase ...

AstraZeneca trades at GBX12,626 today with a marginal gain, supported by positive regulatory and R&D updates and stable price action.